first reported a link between mutations of the TERT promoter and BRAF (V600E) in PTC, and subsequent studies further demonstrated the coexistence of TERT promoter and BRAF(V600E) mutations in thyroid cancers and their association with the most aggressive PTC clinical factors and worse prognosis (47–50). This evidence concerns the gene TERT and thyroid cancer.